Rat Hippocampal Plasticity Remained Altered When THC Was Undetectable in the Sampled Tissue

A 2007 rat experiment found persistent changes in hippocampal long-term potentiation after repeated THC, at a time when THC was undetectable in sampled hippocampal tissue by the reported assay. Chemical detectability and a lasting functional adaptation were separate observations.

The endpoint was measured in brain slices

Electrophysiological recordings assessed long-term potentiation after different exposure durations. The result was a synaptic-plasticity measure, not a direct test of human memory or a clinical diagnosis. Absence of detection also remains bounded by the assay and sampling conditions.

Duration and recovery mattered

Several days of repeated exposure disrupted the measured potentiation, with effects persisting after dosing stopped. A single acute exposure did not produce the same reported pattern. Those differences make the regimen and post-dose interval essential to interpretation.

Not all synaptic responses adapted equally

The study found tolerance on inhibition of GABA release but not the corresponding glutamate response. Antagonist pretreatment also modified potentiation findings. These comparisons support distinct synaptic mechanisms without proving that every observed change shares one cause.

Interpreting the evidence

This study illustrates why a concentration result and a functional assay cannot substitute for one another. It does not establish a human memory-recovery timeline, universal lasting injury or an individual's impairment after THC becomes analytically undetectable.

Related reading: interpreting cannabis tolerance claims.

Research reference

Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR (2007). Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learning & memory (Cold Spring Harbor, N.Y.). doi:10.1101/lm.439007.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us